BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2023 1:46:53 PM | Browse: 523 | Download: 1650
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 86605
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
Manuscript Source Unsolicited Manuscript
All Author List Wen-Hui Luo, Shao-Jun Li and Xue-Feng Wang
ORCID
Author(s) ORCID Number
Wen-Hui Luo http://orcid.org/0009-0005-5081-0305
Shao-Jun Li http://orcid.org/0009-0007-3652-4905
Xue-Feng Wang http://orcid.org/0009-0003-1923-9919
Funding Agency and Grant Number
Corresponding Author Xue-Feng Wang, MD, Associate Chief Physician, Doctor, Doctor, The Second Department of Hepatobiliary Surgery, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai 264000, Shandong Province, China. seasonslo@126.com
Key Words Cholangiocarcinoma; Immune-checkpoint-inhibitor; Lenvatinib; Sintilimab; Epigastric metastasis; Immunotherapy; Case report
Core Tip Cholangiocarcinoma (CCA) is a highly lethal hepatobiliary neoplasm. This report presents a case with advanced CCA who received immunotherapy, revealing differences in treatment responses between intrahepatic vs. extrahepatic epigastric metastatic sites. This hitherto unreported phenomenon prompted us to investigate the differential outcomes of these metastatic patterns following treatment with lenvatinib combined with sintilimab, culminating in a summary report elucidating potential underlying mechanisms.
Publish Date 2023-11-15 13:46
Citation Luo WH, Li SJ, Wang XF. Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature. World J Gastrointest Oncol 2023; 15(11): 2033-2040
URL https://www.wjgnet.com/1948-5204/full/v15/i11/2033.htm
DOI https://dx.doi.org/10.4251/wjgo.v15.i11.2033
Full Article (PDF) WJGO-15-2033-with-cover.pdf
Full Article (Word) WJGO-15-2033.docx